Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Long-Term Deferred Tax: 2018-2025

Historic Long-Term Deferred Tax for China SXT Pharmaceuticals (SXTC) over the last 7 years, with Mar 2025 value amounting to -$1.4 million.

  • China SXT Pharmaceuticals' Long-Term Deferred Tax fell 14.59% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 14.59%. This contributed to the annual value of -$1.4 million for FY2025, which is 15.34% down from last year.
  • China SXT Pharmaceuticals' Long-Term Deferred Tax amounted to -$1.4 million in FY2025, which was down 15.34% from -$1.3 million recorded in FY2024.
  • China SXT Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $321,444 for FY2021, and its period low was -$1.4 million during FY2025.
  • Its 3-year average for Long-Term Deferred Tax is -$1.2 million, with a median of -$1.3 million in 2024.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Long-Term Deferred Tax soared by 184.87% in 2021 and then crashed by 42.58% in 2024.
  • Over the past 4 years, China SXT Pharmaceuticals' Long-Term Deferred Tax (Yearly) stood at $321,444 in 2021, then reached -$876,804 in 2023, then slumped by 42.58% to -$1.3 million in 2024, then declined by 15.34% to -$1.4 million in 2025.